RAD51 and prostate carcinoma: • Enhances HR activity, D-loop formation and the formation of toxic RAD51 complexes on undamaged chromatin.• Leads to the accumulation of RAD51 foci in prostate cancer cells but not in normal cells which is independent of DNA damage.• Enhances cellular resistance to cisplatin at ~7.5 μM.